AXL and non-small cell lung carcinoma: In this respect, combination therapies involving EGFR TKIs and an inhibitor of AXL (either an antibody or a small molecule) were able to prevent resistance to EGFR TKIs in EGFR-mutated NSCLC models [123,157].